SAN FRANCISCO, Oct. 29, 2020 /PRNewswire/ -- Nektar
Therapeutics (NASDAQ: NKTR) announced today that it will webcast an
analyst and investor conference call at ACR 2020 with company
management and Dr. Klatzmann of Sorbonne University on Wednesday, November 4, 2020 at 4:15 p.m. EST. The event will follow Wednesday's
virtual release by ACR of the poster presentation of data from
Nektar's Phase 1b multiple ascending
dose study of NKTR-358, a first-in-class investigational regulatory
T cell stimulator, in patients with systemic lupus erythematosus.
The poster will be displayed online from November 4, 2020 to March
11, 2021.
Analyst Call with Immunology Expert
Date and Time: Wednesday, November 4, 2020
at 4:15 p.m. Eastern Standard Time
Dial- in: (877) 881-2183 (toll-free) or (970)
315-0453 (access code 7083115)
The call will include a presentation of the NKTR-358 data from
ACR 2020 and a discussion with immunology expert, Dr. David
Klatzmann, Professor of Immunology at the Pierre & Marie Curie
Medical School and chairman of the
Inflammation-Immunopathology-Biotherapy Department at Sorbonne
University. Investors and analysts can view slides and listen
to the live audio webcast of the presentation at
https://edge.media-server.com/mmc/p/yppmbgt9. The event will also
be available for replay for two weeks on the company's
website, www.nektar.com.
Details of the virtual interactive poster presentation at ACR
2020 for NKTR-358 are as follows:
Date: Monday, November 9, 2020, 9:00 – 11:00 a.m. Eastern Standard Time
Session Title: SLE – Treatment Poster II
Abstract Title: C. Fanton, et al., "Selective Expansion
of Regulatory T Cells in Patients with Systemic Lupus Erythematosus
by a Novel IL-2 Conjugate, NKTR-358"
Abstract: 1824
Presenter: Dr. Richard Alan Furie, Professor,
Center for Autoimmune, Musculoskeletal and Hematopoietic Diseases,
Feinstein Institutes for Medical Research
About NKTR-358 (LY3471851)
Autoimmune and inflammatory diseases cause the immune system to
mistakenly attack and damage healthy cells in a person's body. A
failure of the body's self-tolerance mechanisms enables the
formation of the pathogenic T lymphocytes that conduct this attack.
NKTR-358 is a potential first-in-class therapeutic that may address
an underlying immune system imbalance in people with many
autoimmune conditions. It targets the interleukin (IL-2)
receptor complex in the body in order to stimulate proliferation of
inhibitory immune cells known as regulatory T cells. By activating
these cells, NKTR-358 may act to bring the immune system back into
balance. Nektar entered into a strategic collaboration with Lilly
in 2017 to develop and commercialize NKTR-358.
NKTR-358 is being developed by Lilly as a self-administered
injection for a number of autoimmune and inflammatory
diseases. A Phase 2 study of NKTR-358 is underway in adults
with systemic lupus erythematosus (ISLAND-SLE) (NCT04433585). The
investigational therapy is also currently being evaluated in two
separate Phase 1b studies in patients
with atopic dermatitis (NCT04081350) and psoriasis
(NCT04119557).
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a
robust, wholly owned R&D pipeline of investigational medicines
in oncology and immunology as well as a portfolio of approved
partnered medicines. Nektar is headquartered in San Francisco, California, with additional
operations in Huntsville, Alabama
and Hyderabad, India. Further
information about the company and its drug development programs and
capabilities may be found online at http://www.nektar.com.
Cautionary Note Regarding Forward-Looking
Statements
This press release contains forward-looking statements which
can be identified by words such as: "may," "can," "will" and
similar references to future periods. Examples of forward-looking
statements include, among others, statements we make regarding the
expected benefits of NKTR-358, the ability to obtain useful data
from clinical studies of NKTR-358, and the future clinical
development plans for NKTR-358. Forward-looking statements
are neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations
and assumptions regarding the future of our business, future plans
and strategies, anticipated events and trends, the economy and
other future conditions. Because forward-looking statements relate
to the future, they are subject to inherent uncertainties, risks
and changes in circumstances that are difficult to predict and many
of which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
to differ materially from those indicated in the forward-looking
statements include, among others: (i) NKTR-358 is in early-stage
clinical development and there are substantial risks that can
unexpectedly occur for numerous reasons including negative safety
and efficacy findings in clinical studies notwithstanding positive
findings in prior studies; (ii) clinical study outcomes of NKTR-358
remain very unpredictable and it is possible that a given clinical
study could fail due to efficacy, safety or other important
clinical findings, wherein any failure of a clinical trial for
NKTR-358 in a particular indication could prevent further
development for all indications; (iii) the timing of the
commencement or end of clinical trials and the availability of
clinical data may be delayed or unsuccessful due to regulatory
delays, slower than anticipated patient enrollment, manufacturing
challenges, changing standards of care, evolving regulatory
requirements, clinical trial design, clinical outcomes, and
competitive factors; (iv) scientific discovery of new therapeutics
is an inherently uncertain process and the future success of
applying our technology platform to potential new drug candidates
(such as NKTR-358) is therefore highly uncertain and unpredictable;
(v) patents may not issue from our patent applications for
NKTR-358, patents that have issued may not be enforceable, or
additional intellectual property licenses from third parties may be
required; and (vi) certain other important risks and uncertainties
set forth in Nektar's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August
7, 2020. Any forward-looking statement made by us in this
press release is based only on information currently available to
us and speaks only as of the date on which it is made. We undertake
no obligation to update any forward-looking statement, whether
written or oral, that may be made from time to time, whether as a
result of new information, future developments or
otherwise.
Contact:
For Investors:
Jerry
Isaacson of Nektar Therapeutics
628-895-0634
Vivian Wu of Nektar
Therapeutics
628-895-0661
View original
content:http://www.prnewswire.com/news-releases/nektar-therapeutics-to-host-webcast-conference-call-for-analysts--investors-for-2020-american-college-of-rheumatology-acr-congress-301163490.html
SOURCE Nektar Therapeutics